Bristol Myers Squibb on Sunday announced that it has entered into a definitive merger agreement with cancer-focused biotech Mirati Therapeutics in a bid to grow its oncology franchise.
https://www.pharmalive.com/wp-content/uploads/2023/05/BMS-building.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-10-09 08:30:492023-10-09 10:28:12BMS buys Mirati for $4.8B to boost cancer business
